盘龙药业(002864) - 002864盘龙药业投资者关系管理信息20250620

Group 1: R&D Strategy and Product Layout - The company focuses on innovative management in the field of orthopedic chronic diseases, establishing a dual-driven R&D system of "independent innovation + industrial collaboration" [2] - Key areas of R&D include traditional Chinese medicine innovative drugs, hospital preparations, and Chinese medicine formula granules, alongside chemical generic drugs [2] - The company aims to form a differentiated product matrix and strengthen industrial collaboration through a dual layout of industry funds [2] Group 2: Cost Advantages and Supply Chain - The company has established significant industrial chain synergy in the Chinese medicine formula granules sector, leading to unique cost competitiveness [3] - It is actively promoting deep integration of the raw material supply system through scale procurement and vertical integration [3] - The company is constructing a complete industrial chain closed loop from raw material planting, production processing to terminal sales, maximizing efficiency across all stages [3] Group 3: Marketing and Product Development - The company emphasizes innovation in the health industry and is actively implementing scenario-based marketing strategies to enhance brand influence and product competitiveness [3] - Multiple new products have been independently developed in the health supplement sector, with some entering the production preparation stage [3] - The company is exploring diversified marketing models to improve product visibility and brand impact, targeting specific consumer groups [3]